Neuphoria Therapeutics (NEUP) Q2 2025 earnings summary

Executive summary

• Clinical-stage biotech focused on neuropsychiatric disorders, advancing BNC210 for PTSD and SAD, with a strategic partnership with Merck for Alzheimer's and CNS indications.

• Completed redomiciliation from Australia to Delaware in December 2024, now trading on Nasdaq as NEUP.

• No product revenue to date; operations funded by equity, milestone payments, and government grants.

Financial highlights

• Cash and cash equivalents were $4.3 million as of December 31, 2024, down from $12.6 million at June 30, 2024.

• Net loss was $1.9 million for the quarter and $2.7 million for the six months ended December 31, 2024, both significantly improved from prior year periods.

• Revenue of $0.66 million in the quarter, driven by a milestone payment from Carina Biotech.

• Operating expenses decreased year-over-year, with R&D down 14.6% and G&A up 4.4% for the quarter.

• Other income increased due to fair value adjustments on warrants and foreign currency gains.

Outlook and guidance

• Existing cash, expected milestone from Merck, and ATM facility projected to fund operations into Q4 FY2026.

• Ongoing need for additional capital to support clinical development and commercialization activities.